Birgitte Preiss

Epidemiology and Clinical Significance of Secondary and Therapy-Related Acute Myeloid Leukemia: A National Population-Based Cohort Study

Lene Sofie Granfeldt Østgård, Bruno C. Medeiros, Henrik Sengeløv et al. · Journal of Clinical Oncology · 2015 · 436 citations · Full text

Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population

Rasmus Sørrig, Tobias Wirenfeldt Klausen, Morten Salomo et al. · PLoS ONE · 2017 · 51 citations · Full text

Proteasome inhibitors and <scp>IM</scp>iDs can overcome some high‐risk cytogenetics in multiple myeloma but not gain 1q21

Hareth Nahi, Thea Kristin Våtsveen, Johan Lund et al. · European Journal Of Haematology · 2015 · 40 citations

Proteasome Inhibitors, Mixed-phenotype Acute Leukemia, Immunology +18

NPM1 mutation is a stable marker for minimal residual disease monitoring in acute myeloid leukaemia patients with increased sensitivity compared to WT1 expression*

Thomas Kielsgaard Kristensen, Michael Møller, Lone Smidstrup Friis et al. · European Journal Of Haematology · 2011 · 39 citations

Npm1 Mutation, Mixed-phenotype Acute Leukemia, Genetics +17

Cytogenetic findings in adult <i>de novo</i> acute myeloid leukaemia. A population‐based study of 303/337 patients

Birgitte Preiss, Gitte Kerndrup, Kai Gjerløff Schmidt et al. · British Journal of Haematology · 2003 · 37 citations · Full text